Evotec - Research never stops
  • Loading...

Andromeda/Teva: DiaPep277

DiaPep277 is a proprietary oligopeptide of 24 amino acids derived from the sequence of the human heat shock protein 60 (Hsp60). The peptide acts by modulating the immune system, preventing the destruction of pancreatic cells that secrete insulin and preserving their natural function.

There is a development partnership with Andromeda on DiaPep277 to treat type 1 diabetes, which is in pivotal Phase III clinical development. Evotec will receive royalties upon commercialisation of DiaPep277 products by Andromeda’s distribution partner Teva and significant milestones upon the successful completion of key development and regulatory milestones.